These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 37997789)

  • 21. Antivascular endothelial growth factors in the treatment of macular oedema secondary to central retinal vein occlusion: a meta-analysis.
    Zhou S; Gao J; Xu X
    Clin Exp Ophthalmol; 2014; 42(7):637-49. PubMed ID: 24330277
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Visual Outcomes Associated With Patterns of Macular Edema Resolution in Central Retinal Vein Occlusion Treated With Anti-Vascular Endothelial Growth Factor Therapy: A Post Hoc Analysis of the Lucentis, Eylea, Avastin in Vein Occlusion (LEAVO) Trial.
    Gurudas S; Patrao N; Nicholson L; Sen P; Ramu J; Sivaprasad S; Hykin P
    JAMA Ophthalmol; 2022 Feb; 140(2):143-150. PubMed ID: 34989804
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intravitreal dexamethasone implant versus anti-VEGF injection for treatment-naïve patients with retinal vein occlusion and macular edema: a 12-month follow-up study.
    Chiquet C; Dupuy C; Bron AM; Aptel F; Straub M; Isaico R; Romanet JP; Creuzot-Garcher C
    Graefes Arch Clin Exp Ophthalmol; 2015 Dec; 253(12):2095-102. PubMed ID: 25673251
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of off-label anti-vascular endothelial growth factor and steroid implant medication uses in macular edema due to retinal vein occlusion in Turkey.
    Yilmaz M; Citirik M; Rahmanlar H; Alkan A; Gursoz H
    J Clin Pharm Ther; 2022 Dec; 47(12):2101-2106. PubMed ID: 36543255
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusion.
    Braithwaite T; Nanji AA; Lindsley K; Greenberg PB
    Cochrane Database Syst Rev; 2014 May; 2014(5):CD007325. PubMed ID: 24788977
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fluctuations in Macular Thickness in Patients with Retinal Vein Occlusion Treated with Anti-Vascular Endothelial Growth Factor Agents.
    Chen AX; Greenlee TE; Conti TF; Briskin IN; Singh RP
    Ophthalmol Retina; 2020 Dec; 4(12):1158-1169. PubMed ID: 32480014
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-vascular endothelial growth factor treatment for retinal conditions: a systematic review and meta-analysis.
    Pham B; Thomas SM; Lillie E; Lee T; Hamid J; Richter T; Janoudi G; Agarwal A; Sharpe JP; Scott A; Warren R; Brahmbhatt R; Macdonald E; Straus SE; Tricco AC
    BMJ Open; 2019 May; 9(5):e022031. PubMed ID: 31142516
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Consequences of anti-vascular endothelial growth factor treatment lapse in patients with retinal vein occlusion.
    Liu JC; Alsaloum P; Iyer AI; Kaiser PM; Singh RP
    Eye (Lond); 2023 Feb; 37(3):453-458. PubMed ID: 35132210
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Role of Serum Inflammation-Based Factors in Anti-Vascular Endothelial Growth Factor Treatment for Macular Edema Secondary to Retinal Vein Occlusion and Its Subtypes.
    Rao J; Wu N; Qu X; Hu Y; Wu Y; Cheng Y; Yan L; Huang H; Li S; Shi L; Wu X
    Ophthalmic Res; 2021; 64(2):237-245. PubMed ID: 32506058
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The correlation between cytokine levels in the aqueous humor and the prognostic value of anti-vascular endothelial growth factor therapy for treating macular edema resulting from retinal vein occlusion.
    Yong H; Qi H; Yan H; Wu Q; Zuo L
    Graefes Arch Clin Exp Ophthalmol; 2021 Nov; 259(11):3243-3250. PubMed ID: 34059950
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real-World Outcomes of Anti-VEGF Treatment for Retinal Vein Occlusion in Portugal.
    Vaz-Pereira S; Marques IP; Matias J; Mira F; Ribeiro L; Flores R
    Eur J Ophthalmol; 2017 Nov; 27(6):756-761. PubMed ID: 28315518
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Short-term and long-term results after intravitreal bevacizumab therapy for macular oedema in branch retinal vein occlusion.
    Pidro A; Pidro A; Nadarevic-Vodencarevic A; Halilbasic M; Lepara O; Nisic F
    Rom J Ophthalmol; 2022; 66(1):22-26. PubMed ID: 35531462
    [No Abstract]   [Full Text] [Related]  

  • 33. Predictors of Visual Acuity Outcomes after Anti-Vascular Endothelial Growth Factor Treatment for Macular Edema Secondary to Central Retinal Vein Occlusion.
    Sen P; Gurudas S; Ramu J; Patrao N; Chandra S; Rasheed R; Nicholson L; Peto T; Sivaprasad S; Hykin P
    Ophthalmol Retina; 2021 Nov; 5(11):1115-1124. PubMed ID: 33610836
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Retinal Vein Occlusion.
    Sawada O; Ohji M
    Dev Ophthalmol; 2016; 55():147-53. PubMed ID: 26501219
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reading speed improvements in retinal vein occlusion after ranibizumab treatment.
    Suñer IJ; Bressler NM; Varma R; Lee P; Dolan CM; Ward J; Colman S; Rubio RG
    JAMA Ophthalmol; 2013 Jul; 131(7):851-6. PubMed ID: 23699977
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SCORE2 Report 2: Study Design and Baseline Characteristics.
    Scott IU; VanVeldhuisen PC; Ip MS; Blodi BA; Oden NL; Figueroa M; Dugel PU;
    Ophthalmology; 2017 Feb; 124(2):245-256. PubMed ID: 27863843
    [TBL] [Abstract][Full Text] [Related]  

  • 37. EFFICACY AND FREQUENCY OF INTRAVITREAL AFLIBERCEPT VERSUS BEVACIZUMAB FOR MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION.
    Lotfy A; Solaiman KAM; Abdelrahman A; Samir A
    Retina; 2018 Sep; 38(9):1795-1800. PubMed ID: 28767552
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outcomes of switching treatment to aflibercept in patients with macular oedema secondary to central retinal vein occlusion refractory to ranibizumab.
    Konidaris V; Al-Hubeshy Z; Tsaousis KT; Gorgoli K; Banerjee S; Empeslidis T
    Int Ophthalmol; 2018 Feb; 38(1):207-213. PubMed ID: 28405787
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Aflibercept for Previously Treated Macular Edema Associated with Central Retinal Vein Occlusions: 1-Year Results of the NEWTON Study.
    Khurana RN; Chang LK; Bansal AS; Palmer JD; Wu C; Wieland MR
    Ophthalmol Retina; 2018 Feb; 2(2):128-133. PubMed ID: 31047339
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 12-month outcomes of ranibizumab versus aflibercept for macular oedema in central retinal vein occlusion: data from the FRB! registry.
    Niedzwiecki M; Hunt A; Nguyen V; Mehta H; Creuzot-Garcher C; Gabrielle PH; Guillemin M; Fraser-Bell S; Arnold J; McAllister IL; Gillies M; Barthelmes D
    Acta Ophthalmol; 2022 Jun; 100(4):e920-e927. PubMed ID: 34519167
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.